Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!
May 27, 2019
The U.S. FDA recently approved the much talked about Novartis’s drug Zolgensma for treating a life-threatening condition Spinal Muscular Atrophy (SMA). SMA is a neuromuscular disorder that worsens the muscles over time. It happens due to a mutation in the SMN1 gene that results in the deficiency of an SMN pro...
Read More...
May 06, 2019
SMA (Spinal Muscular Atrophy) - a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or breathing. Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028). ...
Read More...
Apr 29, 2019
Spinal muscular atrophy (SMA) being a rare genetic neuromuscular disorder results in progressive muscle weakness and atrophy. It affects the part of the nervous system that controls voluntary muscle movement. Spinal Muscular Atrophy Current therapeutic management revolves around supportive and multidisciplinary car...
Read More...
Apr 26, 2019
Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons in the Spinal Cord. SMA is one of the most common causes of infant mortality and mobility impairment. Spinal Muscular A...
Read More...
Apr 24, 2019
Spinal muscular atrophy is a genetic disorder characterised by weakness and wasting (atrophy) of skeletal muscles, used for movement. Loss of specialised nerve cells, called motor neurons which controls muscle movement, results in weakness of muscles. It mostly affects proximal muscles and respiratory muscles. SMA ...
Read More...
Oct 25, 2018
Innovent Biologics reaps USD 421 Million by Hong Kong IPO Innovent Biologics got delivered USD 421 million in its IPO. The Suzhou-based unicorn priced 236.35 million shares near the top of the range at HK USD 13.98. The USD 245 million is given by a group of 10 cornerstone investors, because of which Innovent’s tot...
Read More...
Aug 11, 2016
Spinal Muscular Atrophy (SMA) is a rare genetic and neuromuscular condition which affects mainly children. It has several distinct types such as type 1 (Werdnig-Hoffmann disease), type 2 (Dubowitz disease), type 3 (Kugelberg-Welander disease) and type 4 (Adult onset). SMN1 (Survival Motor Neuron 1) is the primary ge...
Read More...
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Transforming Multiple Myeloma Treatment: The Promise of Novel Drug Classes
Jul 24, 2024
Newsletter/Whitepaper